AroCell Past Earnings Performance
Past criteria checks 0/6
AroCell's earnings have been declining at an average annual rate of -27.5%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 71.4% per year.
Key information
-27.5%
Earnings growth rate
12.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 71.4% |
| Return on equity | -36.2% |
| Net Margin | -137.8% |
| Next Earnings Update | 21 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AroCell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 43 | -59 | 33 | 25 |
| 30 Sep 23 | 46 | -59 | 35 | 26 |
| 30 Jun 23 | 46 | -57 | 35 | 25 |
| 31 Mar 23 | 40 | -57 | 35 | 25 |
| 31 Dec 22 | 37 | -59 | 36 | 24 |
| 30 Sep 22 | 30 | -62 | 36 | 24 |
| 30 Jun 22 | 26 | -69 | 37 | 25 |
| 31 Mar 22 | 20 | -59 | 31 | 23 |
| 31 Dec 21 | 12 | -50 | 26 | 20 |
| 30 Sep 21 | 6 | -36 | 18 | 16 |
| 30 Jun 21 | 0 | -25 | 12 | 13 |
| 31 Mar 21 | 0 | -25 | 12 | 13 |
| 31 Dec 20 | 0 | -24 | 11 | 13 |
| 30 Sep 20 | 0 | -24 | 12 | 12 |
| 30 Jun 20 | 0 | -22 | 12 | 11 |
| 31 Mar 20 | 0 | -21 | 11 | 10 |
| 31 Dec 19 | 0 | -21 | 11 | 10 |
| 30 Sep 19 | 0 | -20 | 10 | 10 |
| 30 Jun 19 | 0 | -21 | 11 | 10 |
| 31 Mar 19 | 1 | -22 | 11 | 10 |
| 31 Dec 18 | 1 | -21 | 10 | 10 |
| 30 Sep 18 | 1 | -21 | 11 | 10 |
| 30 Jun 18 | 1 | -19 | 10 | 9 |
| 31 Mar 18 | 0 | -17 | 9 | 8 |
| 31 Dec 17 | 1 | -17 | 10 | 8 |
| 30 Sep 17 | 0 | -13 | 9 | 5 |
| 30 Jun 17 | 0 | -12 | 9 | 4 |
| 31 Mar 17 | 0 | -11 | 10 | 1 |
| 31 Dec 16 | 0 | -9 | 7 | 2 |
| 30 Sep 16 | 1 | -9 | 8 | 2 |
| 30 Jun 16 | 0 | -8 | 8 | 1 |
| 31 Mar 16 | 0 | -8 | 8 | 1 |
| 31 Dec 15 | 0 | -7 | 8 | 0 |
| 30 Sep 15 | 0 | -9 | 9 | 0 |
| 30 Jun 15 | 0 | -8 | 8 | 0 |
| 31 Mar 15 | 0 | -8 | 8 | 0 |
| 31 Dec 14 | 0 | -6 | 6 | 0 |
| 30 Sep 14 | 0 | -5 | 5 | 0 |
| 30 Jun 14 | 0 | -5 | 4 | 0 |
| 31 Mar 14 | 0 | -4 | 4 | 0 |
| 31 Dec 13 | 0 | -4 | 4 | 0 |
| 30 Sep 13 | 0 | -3 | 3 | 0 |
Quality Earnings: 80R is currently unprofitable.
Growing Profit Margin: 80R is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 80R is unprofitable, and losses have increased over the past 5 years at a rate of 27.5% per year.
Accelerating Growth: Unable to compare 80R's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 80R is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: 80R has a negative Return on Equity (-36.23%), as it is currently unprofitable.